Genentech ’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone
The inavolisib combination has the potential to address resistance to treatment and poor...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | HER2 | Hormones | Pharmaceuticals